Literature DB >> 14511336

Inhibition of neurokinin-1-substance P receptor and prostanoid activity prevents and reverses the development of morphine tolerance in vivo and the morphine-induced increase in CGRP expression in cultured dorsal root ganglion neurons.

Kelly J Powell1, Remi Quirion, Khem Jhamandas.   

Abstract

Chronic treatment with opioid drugs such as morphine leads to the development of tolerance, which manifests as a loss of drug potency. The mechanisms underlying this phenomenon are poorly understood, but recent evidence suggests that increased activity of nociceptive sensory transmitters [calcitonin gene-related peptide (CGRP) and substance P] and other signalling messengers (prostaglandins) contribute to its development. Chronic intrathecal morphine administration to rats for 7 days produced analgesic tolerance. Co-administration of SR140333, a selective substance P receptor (neurokinin-1) antagonist, or nimesulide, a cyclooxygenase-2-selective inhibitor, augmented the acute effects of morphine, prevented morphine tolerance and reversed established tolerance. In cultured adult dorsal root ganglion neurons, exposure to morphine for 5 days increased the number of neurons expressing CGRP immunoreactivity. Co-exposure with the peptide CGRP receptor antagonist CGRP8-37, SR140333 or nimesulide prevented the morphine-induced increase in the expression of CGRP immunoreactivity. Additionally, BIBN4096BS, a nonpeptide CGRP receptor antagonist, stereoselectively produced similar effects. In summary, this investigation demonstrates that activity of CGRP and substance P contributes to both the induction and expression of opioid analgesic tolerance. Additionally, it highlights the involvement of prostaglandins generated by spinal cyclooxygenase-2 activity in the genesis of opioid tolerance. The neuropeptide and prostanoid activity contributing to tolerance is expressed at the level of the primary afferents terminating in the spinal cord. The combination of opioids with agents that block this activity may represent a useful strategy for the prevention as well as the reversal of clinical opioid tolerance.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14511336     DOI: 10.1046/j.1460-9568.2003.02887.x

Source DB:  PubMed          Journal:  Eur J Neurosci        ISSN: 0953-816X            Impact factor:   3.386


  36 in total

1.  Biological and conformational evaluation of bifunctional compounds for opioid receptor agonists and neurokinin 1 receptor antagonists possessing two penicillamines.

Authors:  Takashi Yamamoto; Padma Nair; Neil E Jacobsen; Vinod Kulkarni; Peg Davis; Shou-Wu Ma; Edita Navratilova; Henry I Yamamura; Todd W Vanderah; Frank Porreca; Josephine Lai; Victor J Hruby
Journal:  J Med Chem       Date:  2010-08-12       Impact factor: 7.446

2.  Tachykinin NK₁ receptor antagonist co-administration attenuates opioid withdrawal-mediated spinal microglia and astrocyte activation.

Authors:  Suneeta Tumati; Tally M Largent-Milnes; Attila I Keresztes; Takashi Yamamoto; Todd W Vanderah; William R Roeske; Victor J Hruby; Eva V Varga
Journal:  Eur J Pharmacol       Date:  2012-06-05       Impact factor: 4.432

3.  Neurokinin 1 and opioid receptors: relationships and interactions in nervous system.

Authors:  Jie Xiao; Si Zeng; Xiangrui Wang; Hasan Babazada; Zhanchun Li; Renyu Liu; Weifeng Yu
Journal:  Transl Perioper Pain Med       Date:  2016

4.  Spinal or systemic TY005, a peptidic opioid agonist/neurokinin 1 antagonist, attenuates pain with reduced tolerance.

Authors:  T M Largent-Milnes; T Yamamoto; P Nair; J W Moulton; V J Hruby; J Lai; F Porreca; T W Vanderah
Journal:  Br J Pharmacol       Date:  2010-11       Impact factor: 8.739

5.  Augmentation of spinal morphine analgesia and inhibition of tolerance by low doses of mu- and delta-opioid receptor antagonists.

Authors:  N S Abul-Husn; M Sutak; B Milne; K Jhamandas
Journal:  Br J Pharmacol       Date:  2007-05-14       Impact factor: 8.739

Review 6.  The role of mitogen-activated protein kinase (MAPK) in morphine tolerance and dependence.

Authors:  Yong Chen; Claudia Sommer
Journal:  Mol Neurobiol       Date:  2009-05-26       Impact factor: 5.590

7.  Spinal mediators that may contribute selectively to antinociceptive tolerance but not other effects of morphine as revealed by deletion of GluR5.

Authors:  A M Gregus; C N Inra; T P Giordano; A C S Costa; A M Rajadhyaksha; C E Inturrisi
Journal:  Neuroscience       Date:  2010-03-29       Impact factor: 3.590

Review 8.  Investigational peptide and peptidomimetic μ and δ opioid receptor agonists in the relief of pain.

Authors:  Aswini Kumar Giri; Victor J Hruby
Journal:  Expert Opin Investig Drugs       Date:  2013-12-13       Impact factor: 6.206

9.  The importance of micelle-bound states for the bioactivities of bifunctional peptide derivatives for delta/mu opioid receptor agonists and neurokinin 1 receptor antagonists.

Authors:  Takashi Yamamoto; Padma Nair; Neil E Jacobsen; Peg Davis; Shou-wu Ma; Edita Navratilova; Sharif Moye; Josephine Lai; Henry I Yamamura; Todd W Vanderah; Frank Porreca; Victor J Hruby
Journal:  J Med Chem       Date:  2008-09-27       Impact factor: 7.446

10.  Decreased substance P and NK1 receptor immunoreactivity and function in the spinal cord dorsal horn of morphine-treated neonatal rats.

Authors:  Lisa M Thomson; Gregory W Terman; Jinsong Zeng; Janet Lowe; Charles Chavkin; Sam M Hermes; Deborah M Hegarty; Sue A Aicher
Journal:  J Pain       Date:  2007-10-24       Impact factor: 5.820

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.